Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

Slides:



Advertisements
Similar presentations
What is Pharmacometrics (PM)?
Advertisements

Matthew M. Riggs, Ph.D. metrum research group LLC
1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
The Statisticians Role in Pharmaceutical Development
1 How New Insights into Pharmacogenomics Lead to Revisions of Product Labels Shiew-Mei Huang, Ph.D. Deputy Director for Science Office of Clinical Pharmacology.
Approaches to incorporating pharmacoeconomic data into early drug discovery Kevin Sheehy Acting CEO Medicines New Zealand.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.
FDA Nasal BA/BE Guidance Overview
Good Clinical Practice GCP
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Exploratory IND Studies
Quality Systems for Clinical Pharmacology and Biopharmaceutics Review Lawrence J. Lesko, Ph.D. Director, Office of Clinical Pharmacology and Biopharmaceutics.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
CPTR Overview CPTR 2012 Workshop October 2-4, 2012.
1 QT Evaluation Studies: Pharmacometric Considerations Leslie Kenna, Peter Lee and Yaning Wang Office of Clinical Pharmacology and Biopharmaceutics CDER/FDA.
Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Update: Topics Previously Presented to the CPSC Clinical Pharmacology Subcommittee (CPSC) of the Advisory Committee for Pharmaceutical Science November.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Transition of Biomarkers to Surrogate Endpoints: A Critical Path Initiative….. …..Introduction Clinical Pharmacology Subcommittee of ACPS November 4, 2004.
History of Pediatric Labeling
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.
Clinical Pharmacology Subcommittee (CPSC) Report ACPS Presentation, April 13, 2004 Jürgen Venitz, MD, Ph.D. Goals of the Advisory Subcommittee: To provide.
HIV-1 Resistance Testing in Drug Development Antiviral Drugs Advisory Committee Meeting November 2-3, 1999.
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
Ameeta Parekh, Ph.D. CDER/OCPB CPSC Meeting November 17/18
Introduction to the Topics Lawrence J. Lesko, Ph.D., FCP Office of Clinical Pharmacology Center for Drug Evaluation and Research Food and Drug Administration.
Initiatives Drive Pediatric Drug Development January 30, 2002.
1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.
Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
My Industrial Placement 15 th February Where I work Company: Pfizer Pfizer is the world’s largest research-based pharmaceutical company Division:
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT Ramana S. Uppoor, R.Ph., Ph.D. Division of Clinical Pharmacology-1 Office of Clinical Pharmacology, CDER, FDA.
Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.
Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.
Patient Focused Drug Development An FDA Perspective
Pre-Investigational New Drug (pre-IND) Meeting with FDA
Issues in Hypothesis Testing in the Context of Extrapolation
بسم الله الرّحمن الرّحيم. Dr Sima Sadrai TUMS
MIDD: Perspectives and Possibilities
Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,
Presentation transcript:

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence J. Lesko, Ph.D., FCP Office of Clinical Pharmacology and Biopharmaceutics, CDER, FDA

Review of Meetings to Date 1st: October 22-23, nd: April 22-23, rd: November 17-18, 2003 Input of the CPSC has had a significant impact on the progress made in each of the topic areas discussed at both of these meetings

Main Focus Has Been on Risk Risk assessment –science-based estimates of a risk faced by a special population under- and over-exposed to a drug treatment Risk management –taking action to reduce the risk through dosing adjustment or appropriate label language

New FDA Strategic Plan “…a key element of FDA’s new strategic plan is efficient risk management…” “…to use the best biomedical science to achieve our health policy goals…” “…to make new treatments and technology less risky, with greater predictability and less time from concept to bedside…”

Scope of Topics Quantitative Risk Analysis Using Exposure-Response Relationships Pediatric PK and Analysis of FDA Pediatric Database Pharmacogenetics: Improvement in Existing Therapies Metabolism- and Transport-Based Drug Interactions

Update on Topic Quantitative Risk Analysis Using Exposure- Response Relationships Basically finalized a systematic pharmacometric methodology to apply to dose adjustments –apply to efficacy and/or safety biomarkers and/or clinical endpoints, often taken together, to assess risk/benefit –integrating into routine NDA reviews and, in the future, early meetings with sponsors Evaluation of utility function is a work in progress –approaches discussed at prior meetings have raised awareness and issues –need future dialogue with physicians and statisticians

Today’s Meeting-Topic 1 Introduce a new proposal for an end-of-phase 2A (EOP2A) meeting between FDA and industry Discuss topics for this meeting revolving around evaluation of E-R and prospective dose selection Show case studies of E-R analysis from NDA reviews as models for EOP2A meetings

Today’s Meeting-Topic 2 Methodology for evaluating QT 1. Points-to-consider for PK-PD (QT) study design 2. Use of clinical trial simulation to optimize study design for PK-PD (QT) evaluation 3. Case study illustrating pharmacometric considerations arising from NDA review of QT data

Update on Topic Pediatric PK and Analysis of FDA Pediatric Database PPK study design template –basically complete and utilized as alternative to determining PK in pediatrics –further work on simulation to optimize number of samples, sampling times and number of patients Pediatric database analysis –retrospective evaluation has been challenging and not very successful incomplete datasets, non-optimal study designs etc –likely undertake more selective, case-by-case analysis of pediatric vs adult data

Today’s Meeting-Topic 3 Re-visit the clinical pharmacology principles of the pediatric decision tree with case studies Present a quantitative method to determine similarity in E-R relationships FDA perspective and an academic perspective on experience using the pediatric decision tree

Update on Topic Pharmacogenetics: Improvement in Existing Therapies Polymorphism in metabolizing enzymes that determine variability in drug exposure –focus CYP 2D6, 2C19, 2C9 and TPMT Additional discussion of TPMT and modification of thiopurine labels –pediatric subcommittee of ODAC in July 2003 many issues raised (need, cost, predictive value etc) recommended including PG information in label test should not be required before receiving drug

Today’s Meeting-Topic 4 Shift discussion to the question: what should be done in new drug development for substrates metabolized by polymorphic enzymes? Three expert perspectives: academic, industry and clinician Discussion will influence recommendations in a general pharmacogenetic guidance under development

Update on Topic Metabolism- and Transport-Based Drug Interactions Introduced topic as foundation for subsequent discussion –increased awareness of emerging mechanisms of drug interactions and what to do about them –revision of drug interaction guidance in progress

Today’s Meeting-Topic 5 Get more specific: what should be done to in consideration of new drug interactions of emerging clinical importance Expert opinion on evaluation of CYP 2B6- and CYP 2C8-based metabolic drug interactions Discussion will impact future regulatory advice on these issues

Summary We are asking for CPSC input and advice on 5 separate topics Specific questions to focus discussion will accompany each topic We are confident that your input will help us improve and refine our thinking about these topics